Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Short Interest Down 71.7% in December

Posted by Stephan Jacobs on Dec 26th, 2025

Fidelity Disruptive Medicine ETF (NASDAQ:FMED – Get Free Report) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totaling 2,524 shares, a drop of 71.7% from the November 30th total of 8,926 shares. Based on an average daily volume of 7,740 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the company’s stock are sold short. Currently, 0.1% of the company’s stock are sold short. Based on an average daily volume of 7,740 shares, the days-to-cover ratio is presently 0.3 days.

Fidelity Disruptive Medicine ETF Stock Down 0.6%

Shares of NASDAQ FMED traded down $0.16 on Friday, hitting $27.45. The company had a trading volume of 2,692 shares, compared to its average volume of 5,539. Fidelity Disruptive Medicine ETF has a 12-month low of $20.69 and a 12-month high of $29.07. The firm has a market capitalization of $60.39 million, a P/E ratio of 41.33 and a beta of 1.00. The business has a 50 day moving average of $27.26 and a two-hundred day moving average of $25.31.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Fidelity Disruptive Medicine ETF stock. Jane Street Group LLC grew its holdings in shares of Fidelity Disruptive Medicine ETF (NASDAQ:FMED – Free Report) by 0.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 66,382 shares of the company’s stock after acquiring an additional 499 shares during the period. Jane Street Group LLC owned about 3.16% of Fidelity Disruptive Medicine ETF worth $1,567,000 as of its most recent SEC filing.

Fidelity Disruptive Medicine ETF Company Profile

(Get Free Report)

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.